Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01321541 · ClinicalTrials.gov registry record · Phase 3
Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
A Phase 3 study, sponsored by CTI BioPharma.
- Completed
- Registry status
- Phase 3
- Development phase
- 312
- Enrollment target
NCT01321541: Completed Phase 3 study, sponsored by CTI BioPharma.
NCT01321541 is a Phase 3 study that has completed, run by CTI BioPharma. The registered enrollment target is 312 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01321541, a Phase 3 study, has completed, sponsored by CTI BioPharma.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 312 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
Interventions
- DRUG Pixantrone + Rituximab
- DRUG Gemcitabine + Rituximab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 312 participants |
| Start Date | 2011-04-20 |
| Est. Completion | 2018-09-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01321541
The ClinicalTrials.gov registry entry for NCT01321541 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 312 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CTI BioPharma, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pixantrone + Rituximab is the first listed.
NCT01321541 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01321541 about?
NCT01321541 is a clinical study titled "Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant". The purpose of this study is to evaluate the efficacy of Pixantrone + Rituximab compared to Gemcitabine + Rituximab in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), or follicular grade 3 lymphoma.
What is the current status of trial NCT01321541?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 312 participants. The study started on 2011-04-20. Estimated completion is 2018-09-14.
What interventions are being tested in trial NCT01321541?
The interventions under investigation include: Pixantrone + Rituximab (DRUG), Gemcitabine + Rituximab (DRUG).
Who is sponsoring clinical trial NCT01321541?
This trial is sponsored by CTI BioPharma, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.